Efficacy and Safety of JAK-STAT Inhibitors in the Treatment of Moderate to Severe Plaque Psoriasis: a Meta Analysis
DOI:
https://doi.org/10.53469/jcmp.2024.06(07).13Keywords:
JAK-STAT inhibitor, Plaque psoriasis, Meta-analysisAbstract
Objective: To systematically evaluate the efficacy and safety of JAK-STAT inhibitors in the treatment of moderate to severe plaque psoriasis. Methods: We conducted a computerized search of relevant published literature in the PubMed, EMBASE, and Cochrane Library databases from their inception to May 2024. We included randomized controlled trials comparing JAK-STAT inhibitors to placebo. Two researchers independently screened the literature and extracted data. The quality of the included studies was assessed using the bias risk assessment tool provided in the Cochrane Systematic Reviews Handbook 5.1.0. We performed a meta-analysis on the effectiveness and safety of JAK-STAT inhibitors for treating moderate to severe plaque psoriasis using RevMan 5.4 software. Results: Seven studies with a total of 1830 patients were included. Meta-analysis revealed that in the JAK-STAT inhibitors group, the proportion of patients achieving a 75% reduction in Psoriasis Area and Severity Index (PASI) scores [RR=6.49, 95% CI (4.07, 10.34), P<0.0001], a Static Physician Global Assessment (sPGA) score of 0 or 1 [RR=4.60, 95% CI (3.08, 6.85), P<0.0001], a Dermatology Life Quality Index (DLQI) score of 0 or 1 [RR=2.73, 95% CI (2.16, 3.44), P<0.0001], and an Itching Scale (ISS) score of 0 or 1 [RR=5.84, 95% CI (3.69, 9.24), P<0.0001] was significantly higher than in the placebo group; The incidence of Total AEs in the JAK-STAT inhibitors group was marginally higher than in the placebo group [RR=1.19, 95% CI (1.01, 1.41), P=0.04], with no statistically significant difference in SAEs between the two groups (P>0.05). Conclusion: JAK-STAT inhibitors demonstrate significant clinical efficacy in treating moderate to severe plaque psoriasis, with most adverse reactions being mild to moderate. Patients exhibit good adherence and tolerability, suggesting their potential as an alternative therapy in clinical practice.
References
GRIFFITHS C E M, ARMSTRONG A W, GUDJONSSON J E, et al. Psoriasis [J]. Lancet, 2021, 397(10281): 1301-15.
MAHIL S K, SMITH C H. Psoriasis biologics: a new era of choice [J]. Lancet, 2019, 394(10201): 807-8.
KORMAN N J. Management of psoriasis as a systemic disease: what is the evidence? [J]. Br J Dermatol, 2020, 182(4): 840-8.
NOGUEIRA M, PUIG L, TORRES T. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors [J]. Drugs, 2020, 80(4): 341-52.
ARMSTRONG A W, KONING J W, ROWSE S, et al. Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data [J]. Dermatol Ther (Heidelb), 2017, 7(1): 97-109.
MIOT H A, CRIADO P R, DE CASTRO C C S, et al. JAK-STAT pathway inhibitors in dermatology [J]. An Bras Dermatol, 2023, 98(5): 656-77.
PAPP K A, MENTER A, STROBER B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study [J]. Br J Dermatol, 2012, 167(3): 668-77.
MAMOLO C, HARNESS J, TAN H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis [J]. J Eur Acad Dermatol Venereol, 2014, 28(2): 192-203.
PAPP K, PARISER D, CATLIN M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis [J]. Br J Dermatol, 2015, 173(3): 767-76.
FELDMAN S R, THAÇI D, GOODERHAM M, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis [J]. J Am Acad Dermatol, 2016, 75(6): 1162-70.e3.
PAPP K A, MENTER M A, RAMAN M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis [J]. Br J Dermatol, 2016, 174(6): 1266-76.
ABE M, NISHIGORI C, TORII H, et al. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial [J]. J Dermatol, 2017, 44(11): 1228-37.
ZHANG J, TSAI T F, LEE M G, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study [J]. J Dermatol Sci, 2017, 88(1): 36-45.
HU Q, BIAN Q, RONG D, et al. JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens [J]. Front Bioeng Biotechnol, 2023, 11: 1110765.
WEI X Y, HU D C, GAO Z P, et al. JAK/STAT signaling pathway and its regulation on insect immunity [J]. Yi Chuan, 2023, 45(3): 229-36.
XIN P, XU X, DENG C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases [J]. Int Immunopharmacol, 2020, 80: 106210.
CORICELLO A, MESITI F, LUPIA A, et al. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates [J]. Molecules, 2020, 25(15).
O'SHEA J J, SCHWARTZ D M, VILLARINO A V, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention [J]. Annu Rev Med, 2015, 66: 311-28.
CHAPMAN S, GOLD L S, LIM H W. Janus kinase inhibitors in dermatology: Part II. A comprehensive review [J]. J Am Acad Dermatol, 2022, 86(2): 414-22.
BAI F, ZHENG W, DONG Y, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis [J]. Oncotarget, 2018, 9(1): 1266-78.
RAYCHAUDHURI S P, RAYCHAUDHURI S K. JAK inhibitor: Introduction [J]. Indian J Dermatol Venereol Leprol, 2023, 89(5): 688-90.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zhengjin Zhu, Jun Yan, Xiaofang Liu, Jiayun Li
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
